Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
COSTS AND EXPENSES:    
Research and development $ 3,896 $ 5,170
General and administrative 2,401 1,818
Total costs and expenses 6,297 6,988
Operating loss (6,297) (6,988)
Interest income, net 64 53
Net loss $ (6,233) $ (6,935)
Net loss per common share, basic and diluted (in dollars per share) $ (1.29) $ (8.80)
Weighted average common shares outstanding, basic and diluted (in shares) 4,848,199 787,900